Maximizing Breast Cancer Therapy with Awareness of Potential Treatment-Related Blood Disorders

Area of Science:

• Oncology
• Hematology
• Cancer Therapeutics

Background:

• Breast cancer treatment often involves multimodality approaches, including radiation and chemotherapy.
• Certain patient factors, such as younger age, can influence treatment outcomes and risks.
• Subsequent treatment-induced myelodysplasia and acute myelogenous leukemia (t-MDS/AML) are serious potential side effects.

Purpose of the Study:

• To review the impact of various breast cancer therapies and patient factors on t-MDS/AML incidence.
• To identify specific treatment modalities and patient characteristics associated with increased t-MDS/AML risk.
• To inform clinical practice regarding the selection of less leukemogenic treatment strategies.

Main Methods:

• Literature review summarizing existing data on breast cancer treatment and t-MDS/AML.
• Analysis of the combined effects of radiation, chemotherapy (alkylating agents, anthracyclines), and granulocyte colony-stimulating factor (G-CSF).
• Exploration of potential links between homologous DNA repair deficiency (HRD), PARP inhibitors, and t-MDS/AML risk.

Main Results:

• Radiation and chemotherapy, particularly in younger patients, elevate t-MDS/AML risk.
• Combined radiation and chemotherapy significantly increase risk; anthracycline/alkylating agent combinations are high-risk.
• G-CSF (but not pegylated G-CSF) and potential links with HRD/PARP inhibitors are associated with increased risk.

Conclusions:

• Patient and treatment factors synergistically increase t-MDS/AML risk, especially in younger or triple-negative breast cancer patients.
• Minimizing exposure to leukemogenic treatments, like anthracycline/alkylating agents and G-CSF, is vital.
• Future research should focus on developing effective therapies with lower t-MDS/AML risks and further investigating HRD associations.